GlassScriptPhysician profile
Edna K Villegas
NPI 1427475888
$3,443.45
in general payments reported to CMS, 2019-2025
36 companies · $809 in 2025
The $809 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $605 · 2023: $874 · 2024: $1,156 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,745 · Debt Forgiveness: $93.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,745.04 |
| Debt Forgiveness | $93.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $615.53 | 2021-2025 | |
| Corium, LLC | $359.76 | 2023-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $340.87 | 2021-2025 | Spravato |
| Alkermes, INC. | $249.33 | 2023-2025 | Aristada, Lybalvi |
| Novo Nordisk INC | $193.03 | 2021 | |
| Supernus Pharmaceuticals, INC. | $162.49 | 2023-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $140.31 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $132.72 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $124.30 | 2023-2024 | Ingrezza |
| Tris Pharma INC | $105.31 | 2023-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $97.14 | 2023-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $96.32 | 2023-2025 | Trintellix |
| Baxter Healthcare | $93.84 | 2023 | |
| Lilly USA, LLC | $72.80 | 2021 | |
| Axsome Therapeutics, INC. | $68.43 | 2023-2025 | Auvelity |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edna Villegas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.